Osama A Mohammed, Mahmoud E Youssef, Ahmed S Doghish, Rabab S Hamad, Mustafa Ahmed Abdel-Reheim, Mushabab Alghamdi, Mohannad Mohammad S Alamri, Jaber Alfaifi, Masoud I E Adam, Muffarah Hamid Alharthi, Abdullah Hassan Alhalafi, Emad Bahashwan, Assad Ali Rezigalla, Daad Fuad BinAfif, Sameh Abdel-Ghany, Mohammed A Attia, Elsayed A Elmorsy, Tohada M Al-Noshokaty, Heba Fikry, Lobna A Saleh, Sameh Saber
Non-alcoholic steatohepatitis (NASH) is characterized by liver inflammation, fat accumulation, and collagen deposition. Due to the limited availability of effective treatments, there is a pressing need to develop innovative strategies. Given the complex nature of the disease, employing combination approaches is essential. Hedgehog signaling has been recognized as potentially promoting NASH, and cholesterol can influence this signaling by modifying the conformation of PTCH1 and SMO activity. HSP90 plays a role in the stability of SMO and GLI proteins...
May 5, 2024: European Journal of Pharmaceutical Sciences